14. Chronic inflammatory demyelinating polyneuropathy Clinical trials / Disease details
Clinical trials : 167 / Drugs : 158 - (DrugBank : 38) / Drug target genes : 13 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02967679 (ClinicalTrials.gov) | December 5, 2016 | 8/11/2016 | SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study | SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study | Chronic Inflammatory Demyelinating Polyneuropathy;Peripheral Neuropathy;Charcot-Marie-Tooth Disease;Charcot-Marie-Tooth Disease Type 1A;Charcot-Marie-Tooth Disease, Type 1B;Anti-MAG Neuropathy | Drug: MD1003 | MedDay Pharmaceuticals SA | NULL | Completed | 20 Years | 85 Years | All | 15 | Phase 2 | France |